105 Quick summary: Scientists have developed a microchip technique that uses electronic jolts to detect pancreatic cancer biomarkers with 97% accuracy, significantly outperforming the 79% success rate of traditional invasive biopsies. This breakthrough offers a non invasive diagnostic tool that can distinguish between malignant tumours and benign lesions, potentially sparing patients from unnecessary surgeries while ensuring earlier intervention for a disease that is notoriously difficult to identify. Implementing this technology within healthcare practice could transform public policy regarding cancer screening for high risk individuals, providing a vital pathway towards improving long term survival rates and patient well being through a simple blood draw. Scientists at Oregon Health & Science University have developed a new technique using an electronic jolt and nanoparticles to reveal the telltale signal of an insidious form of cancer. The technique, described in a study published in the journal Small, offers a new way to detect early signs of pancreatic cancer – a particularly deadly type of cancer because it is not detected until it has progressed to later stages that are difficult to treat effectively. The new method would involve a simple blood draw among people who are considered higher risk due to family history or other factors. “The pancreas is deep inside the body. It’s not like skin cancer you can see or a lump that you can feel,” said senior author Stuart Ibsen, PhD, associate professor at OHSU. “By the time people experience jaundice or abdominal pain, it’s usually already progressed to an advanced stage.” The sophisticated technique uses a small electronic jolt on a microchip to collect nanoparticles shed by tumours into blood. The next step involves fluorescent staining to reveal biomarkers associated with pancreatic cancer. In the new collaborative study with OHSU’s Brenden-Colson Center for Pancreatic Care, researchers compared blood drawn from 36 people, including those known to have pancreatic cancer and a control group of people with other non-cancerous forms of pancreatic disorders such as pancreatitis. The study was blinded so the researchers did not know which samples came from the cancer patients. The results were strikingly effective, with a 97% likelihood of correctly distinguishing people with cancer from those with benign pancreatic disease. That is far higher even than direct biopsies of the pancreas itself. Typically, the invasive technique – involving tissue retrieval using ultrasound-guided fine needles – reveals 79% of pancreatic cancers. “The more cancer biomarkers, the brighter the electrodes on the chip become,” Ibsen said. The new technique benefits from the fact that cancerous tumours secrete an abundance of a particular type of nanoparticle – easily sampled with a simple blood draw. “Whatever biomarkers the tumour has are carried on these little particles,” Ibsen said. “Our technology allows us to detect those particles.” Even better, the study demonstrates that scientists can distinguish cancerous pancreatic tumours from benign precancerous lesions, which cannot typically be accomplished through imaging alone. Discerning the difference could mean sparing patients an invasive surgery to remove a mass that turns out to be benign. “The information from our blood test could help the surgeon know whether this is something that really needs to come out,” Ibsen said. Ibsen estimates the technique is probably five years away from clinical use.